255
views
0
recommends
+1 Recommend
1 collections
    1
    shares
      scite_
       
      • Record: found
      • Abstract: found
      • Conference Proceedings: found
      Is Open Access

      REMEDI4ALL: Translating from basic science to the clinic : Establishing a European platform for patient-centric drug repurposing

      Published
      proceedings-article
        1 ,
      ScienceOpen
      RExPO22
      2-3 September, 2022
      Drug Repurposing platform, Medicines repositioning, Patient-centric research, Repurposing policy
      Bookmark

            Abstract

            REMEDI4ALL ( https://remedi4all.org/), an EU-funded multi-year initiative to establish Europe's leadership in the repurposing of medicines, will create a vibrant community of practice and accessible value chain for patient-centric repurposing for any disease. The consortium of 24 leading European organisations will establish and operate a permanent European research and innovation platform comprising the complete value chain for cutting edge, patient-focused repurposing, collaborating with users to execute high potential projects at any phase of development, upskilling all stakeholder groups through a comprehensive education and training portfolio, and advancing cross-sectoral policy dialogue with all relevant stakeholders and thought leaders. The tools and processes developed assembled in REMEDI4ALL will be validated in a portfolio of 4 ambitious preclinical and clinical phase demonstrators, representing high patient need in a variety of disease areas, including oncology, rare and infectious diseases.

            Working closely together with research funders and the patient community, REMEDI4ALL will engage and support a substantial user base and concomitant investments through a permanently sustainable entity, working closely with the permanent European Infrastructures and partners. The community of practice comprises leading academic and clinical facilities and infrastructures, medicines regulators, health technology assessors, public agencies and funders, small and large industry, state-of-the-art artificial intelligence and in silico tools, and a global network of collaborators for optimal knowledge exchange. REMEDI4ALL will substantially increase Europe's capacity to develop high quality repurposed medicines and implement them into market, through its complete value chain and consensus-based policy development mission.

            Content

            Author and article information

            Conference
            ScienceOpen
            27 August 2022
            Affiliations
            [1 ] EATRIS ERIC, De Boelelaan 1118, 1081HZ Amsterdam, The Netherlands
            Author notes
            Author information
            https://orcid.org/0000-0001-7342-7062
            Article
            10.14293/S2199-1006.1.SOR-.PPPACKXA.v1
            ed8f4e75-15af-4f7f-9c2f-aa42021ba061

            This work has been published open access under Creative Commons Attribution License CC BY 4.0 , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Conditions, terms of use and publishing policy can be found at www.scienceopen.com .

            RExPO22
            Maastricht, Netherlands
            2-3 September, 2022
            History
            : 27 August 2022

            Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
            Drug Repurposing platform, Medicines repositioning, Patient-centric research, Repurposing policy

            Comments

            Comment on this article